Biogen Appoints Christopher Viehbacher As President And CEO

Biogen Q2 Results Top Estimates; Boosts FY24 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Thursday net income attributable to the company for the second quarter of $583.6 million or $4.00 per share, higher than $591.6 million or $4.07 per share in the prior-year quarter.

RTTNews | 93 days ago

Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications

Biogen Inc. (BIIB) announced Monday that the European Commission (EC) has granted approval for TOFIDENCETM, a biosimilar monoclonal antibody referencing ROACTEMRA.

RTTNews | 131 days ago

Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

RTTNews | 164 days ago

Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Wednesday net income attributable to the company for the first quarter of $393.4 million or $2.70 per share, higher than $387.9 million or $2.67 per share in the prior-year quarter.

RTTNews | 192 days ago

Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA

Biotechnology company Biogen, Inc. (BIIB) announced Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

RTTNews | 319 days ago

Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter.

RTTNews | 466 days ago

Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.

RTTNews | 557 days ago

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates.

RTTNews | 626 days ago

EURUSD	1.08327	GBPUSD	1.2926	AUDUSD	0.65577
USDJPY	152.983	USDCAD	1.29301	USDCHF	0.86964